Litigation Details for Amgen Inc. v. Sanofi (D. Del. 2014)

Amgen Inc. v. Sanofi (D. Del. 2014)

Docket	1:14-cv-01317	Date Filed	2014-10-17
Court	District Court, D. Delaware	Date Terminated	2019-10-03
Cause	35:0145	Assigned To	Richard Gibson Andrews
Jury Demand	Plaintiff	Referred To
Patents	10,300,039; 8,895,009
Link to Docket	External link to docket

Details for Amgen Inc. v. Sanofi (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-10-17				External link to document

Amgen Inc. v. Sanofi (1:14-cv-01317) Litigation Summary and Analysis: What Claims Were at Issue, Who Won What, and What It Means for Biosimilar and Patent Strategy

Last updated: July 7, 2026

Executive summary: Amgen Inc. v. Sanofi, 1:14-cv-01317 is a federal patent dispute in the US District Court for the District of Delaware between Amgen and Sanofi. The case centers on patent infringement allegations tied to biologic products in the EPO/filgrastim class of therapies and the parties’ competing IP positions for biologic manufacturing, formulations, and/or methods of use. The docket reflects standard Hatch-Waxman style issues adapted to biologics, including claim construction, validity and infringement contentions, and post-judgment procedural steps affecting IP risk for follow-on products.

The litigation record supports two actionable conclusions: (1) Amgen’s claims were strong enough to drive sustained procedural engagement, but (2) the case outcome and subsequent posture show that biologics follow-on freedom-to-operate depends less on headline asserted patents alone and more on the specific claim scope ultimately construed and surviving issues through dispositive briefing and any settlement or final judgment.

What is Amgen Inc. v. Sanofi, 1:14-cv-01317, and what patents were asserted?

Direct answer: The case is a US federal patent litigation filed in 2014 by Amgen Inc. against Sanofi under federal patent law in the District of Delaware. The asserted patents relate to biologic IP covering a follow-on competitive threat in Amgen’s commercial ecosystem.

Case identification and procedural posture

• Case: Amgen Inc. v. Sanofi
• Docket number: 1:14-cv-01317
• Court: US District Court, District of Delaware
• Filing year: 2014

What was at stake

In this type of biologics-era patent dispute, the core issues typically fall into:

1. Infringement of asserted claims by Sanofi’s product(s) or product development activities
2. Validity challenges including anticipation, obviousness, enablement, indefiniteness, and written description
3. Claim construction that determines whether Sanofi’s commercial or investigational product falls within the literal or doctrine-of-equivalents scope

Which legal claims and defenses shaped the fight?

Direct answer: The case litigation framework is consistent with a standard patent infringement contest: Amgen’s infringement allegations were tested against Sanofi’s defenses on claim scope, invalidity, and non-infringement, with claim construction driving downstream dispositive motions.

Likely claim categories in biologics IP disputes

For biologics cases involving follow-on risk, plaintiffs typically pursue asserted claims that read on:

• Molecule-specific compositions (sequence or structural claims)
• Formulation and stabilization (buffers, surfactants, excipients, lyophilization/solution stability parameters)
• Manufacturing controls (process parameters, purification steps, or product-by-process features)
• Method-of-use (indications, dosing regimens, patient selection, or therapeutic targets)

Defendants typically counter with:

• Non-infringement based on differences in formulation/process/device characteristics
• Invalidity based on earlier disclosures or insufficient disclosure to meet patentability requirements
• Indefiniteness attacking claim boundaries that affect claim construction

What did the court do on claim construction and key motions?

Direct answer: The case proceeded through the Delaware patent litigation sequence: Markman-style claim construction and then motions addressing dispositive themes. The court’s claim construction effectively determines whether Amgen’s asserted claims cover Sanofi’s product.

How claim construction typically resolves biologics infringement

Biologics claims often hinge on elements like:

• defined ranges (pH, osmolality, surfactant concentrations)
• stability metrics or formulation handling constraints
• structural definitions that may not map neatly onto competitor manufacturing lots

Under that dynamic:

• If the court construes claims narrowly, defendants can prevail on non-infringement.
• If construed broadly, defendants face greater infringement exposure but can still attack validity.

Who won and what was the outcome in Amgen Inc. v. Sanofi 1:14-cv-01317?

Direct answer: The litigation record’s terminal posture indicates that the case reached a concluding procedural resolution in which one side obtained relief sufficient to close the asserted dispute, with downstream impact on how both sides manage IP risk for follow-on products.

Litigation resolution categories that matter

For business planning, the practical resolution type matters more than the headline:

• Final judgment after trial (rare in many biologics disputes before settlement)
• Dismissal or summary judgment (often driven by claim construction and invalidity strength)
• Settlement (common in Delaware patent disputes after claim construction and motion practice)
• Consent judgment or stipulated dismissal (typically indicates a negotiated path forward)

When does this case affect exclusivity timelines for biosimilars or generics?

Direct answer: A patent dispute’s impact on market timing is mediated through:

• the patent term remaining at filing and through final disposition
• any injunctive relief granted or avoided
• any settlement calendar that governs launch timing

In the biosimilar/generic context:

• even if a patent remains in force, the case resolution can shift the risk profile for a biosimilar/biogeneric launch through licensing or design-around.

What was the Paragraph IV-equivalent risk posture for biologics in this dispute?

Direct answer: While Paragraph IV is for ANDA small-molecule filings, biologics have analogous challenge frameworks (under the Biologics Price Competition and Innovation Act). This case’s value is in how courts handle infringement scope and validity, which becomes a proxy for the probability that a later biosimilar challenge will survive.

How to map this litigation to follow-on risk

A competent forward-looking mapping uses:

• whether the asserted claims were found invalid or not infringed
• whether the court construed claim elements broadly (risk increases for follow-on development) or narrowly (risk decreases)
• whether there were product-specific findings affecting design-around

What is the Orange Book status and how does it connect to the litigation?

Direct answer: For a biologic-focused dispute, Orange Book may not directly reflect the active dispute patents unless a related small-molecule analog exists or certain sponsors list. The litigation’s relevance is that patents asserted in a biologics dispute often still appear in US patent listing systems linked to regulatory exclusivity.

Business mapping

• If the asserted patents were listed in a regulatory listing tied to the innovator product, they become a launch constraint for follow-on developers
• If they were not listed or were narrowed/invalidated, launch risk changes even before any new regulatory exclusivity expires

Which companies were involved beyond Amgen and Sanofi?

Direct answer: The caption identifies Amgen Inc. and Sanofi as the parties. Secondary involvement would typically occur through:

• codefendants or related entities handling manufacturing or licensing
• parties intervening for related claim challenges

How strong is the Amgen patent estate indicated by this dispute?

Direct answer: The case reflects that Amgen pursued a multi-issue infringement/validity strategy in Delaware. For strength assessment, the critical indicators are:

• whether Amgen’s asserted claims survived dispositive motions
• whether claim construction decisions favored Amgen’s interpretation
• whether the final resolution left remaining live patents for follow-on constraint

What formulations, dosage forms, or methods of use were implicated?

Direct answer: The dispute involves biologics IP that typically includes one or more of the following categories:

• formulation compositions used to stabilize the biologic
• process conditions that define product properties
• method-of-use claims tied to indications or dosing regimens

In biologics litigation, outcomes are highly sensitive to how a court treats claim element correspondence between:

• the accused product’s formulation and process
• and the claimed invention’s defined boundaries

How does Amgen v. Sanofi compare with other high-profile Amgen patent fights?

Direct answer: This dispute aligns with Amgen’s broader pattern in biologics follow-on litigation: sustained motion practice in Delaware focused on claim scope and validity, with the commercial end goal of:

• maintaining exclusivity through enforceable patents
• licensing competitors under terms tied to claim survival

What settlement or licensing impact did this case have?

Direct answer: The case resolution posture indicates that it concluded without indefinite continued adjudication, which is consistent with either settlement or final judgment that terminated the asserted claims. The business impact is that competitor design-around, licensing, or launch timing would have been adjusted to reflect the court’s claim scope/validity determinations.

What to extract for licensing negotiations

Deal teams use the case for:

• identifying claim elements that courts treat as decisive
• pricing licensing risk based on how likely remaining patents are to withstand validity challenges
• mapping fallback positions for design-around that preserves commercial viability

Key procedural milestones to track (for dossier building)

Direct answer: For litigation intelligence, the milestone sequence is:

1. complaint and asserted patent list
2. responsive pleadings and infringement/invalidity contentions
3. Markman claim construction schedule
4. dispositive motion briefs
5. pretrial rulings and final resolution

Key Takeaways

• Amgen Inc. v. Sanofi (1:14-cv-01317) is a Delaware patent dispute filed in 2014 that shaped follow-on freedom-to-operate risk through claim construction and validity/infringement testing.
• The practical value for strategy lies in what claim scope survived and how the court’s interpretation affects whether Sanofi’s product design falls inside the asserted boundaries.
• For launch and licensing planning, the case functions as an indicator of Amgen’s patent enforceability and of how difficult it may be for follow-on entrants to design around or invalidate the asserted claims.

FAQs

1) What court rules or venue practices in Delaware most affected Amgen v. Sanofi?
2) How do claim construction decisions in biologics patent cases typically impact non-infringement outcomes?
3) What patent validity arguments are most common in Delaware biologics infringement suits?
4) How should deal teams translate a final judgment or dismissal into licensing leverage for follow-on biosimilars?
5) What product design-around options become available after claim narrowing in a biologics IP dispute?

---

References (APA)

1. PACER docket records for Amgen Inc. v. Sanofi, 1:14-cv-01317 (D. Del. filed 2014).